Clostridium difficile Toxin B is a potent cytotoxin and one of the primary virulence factors produced by Clostridioides difficile, a bacterium responsible for causing severe gastrointestinal infections, especially in hospitalized and immunocompromised individuals. The detection of Toxin B in stool specimens is a critical diagnostic marker for identifying active C. difficile infections (CDI), which often manifest as diarrhea, colitis, and potentially life-threatening complications. Unlike Toxin A, Toxin B has been found to be more cytotoxic and is essential for pathogenesis, even in strains that do not produce Toxin A.
In clinical and research settings, the fecal C. Difficile Toxin B ELISA serves as a qualitative assay that uses a sandwich immunoassay format to identify the presence of Toxin B in stool samples. This test involves coating microtiter wells with a monoclonal antibody specific to Toxin B, followed by the addition of the sample and a secondary HRP-conjugated antibody to form an immunocomplex if the toxin is present. The resulting enzymatic reaction is read spectrophotometrically, with intensity correlating to Toxin B levels in the sample. This method offers high specificity and is instrumental in guiding timely treatment decisions and infection control measures.
The utility of this biomarker extends beyond diagnostics—it is also used in epidemiological surveillance and clinical trials evaluating novel therapies for CDI. Due to the significant impact of C. difficile in healthcare settings, rapid and accurate detection of Toxin B remains a cornerstone of managing infectious outbreaks and improving patient outcomes.
This product is manufactured in USA by Eagle Biosciences.